We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
-1.98%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$868M
AUM Growth
+$59.7M
Cap. Flow
+$69.5M
Cap. Flow %
8.01%
Top 10 Hldgs %
48.78%
Holding
127
New
31
Increased
30
Reduced
21
Closed
29

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$14.1M
2
APGE icon
Apogee Therapeutics
APGE
+$11.9M
3
CLYM
Climb Bio
CLYM
+$11.1M
4
ACLX
Arcellx
ACLX
+$8.7M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$8.33M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$9.7M
2
ABSI icon
Absci
ABSI
+$5.82M
3
CYTK icon
Cytokinetics
CYTK
+$5.61M
4
KRYS icon
Krystal Biotech
KRYS
+$4.76M
5
AXSM icon
Axsome Therapeutics
AXSM
+$4.42M

Sector Composition

Rank Sector Weight
1 Healthcare 65.41%
2 Financials 0.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$190M 21.96%
+350,000
New +$183M
XENE icon
2
Xenon Pharmaceuticals
XENE
$6.6B
$38.8M 4.47%
994,227
+156,840
+19% +$6.27M
APGE icon
3
Apogee Therapeutics
APGE
$10.1B
$32.9M 3.79%
836,283
+244,190
+41% +$11.9M
MDGL icon
4
Madrigal Pharmaceuticals
MDGL
$12.8B
$30.8M 3.55%
110,000
-5,000
-4% -$1.19M
ACLX
5
DELISTED
Arcellx
ACLX
$25.4M 2.93%
460,000
+160,000
+53% +$8.7M
TEVA icon
6
Teva Pharmaceuticals
TEVA
$37.3B
$23.6M 2.72%
1,450,000
+50,000
+4% +$770K
CRNX icon
7
Crinetics Pharmaceuticals
CRNX
$8.88B
$23.1M 2.66%
515,000
+45,000
+10% +$2.08M
CERE
8
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$20.4M 2.36%
500,000
+200,000
+67% +$8.33M
NRIX icon
9
Nurix Therapeutics
NRIX
$2.4B
$19M 2.19%
912,000
+101,747
+13% +$1.58M
TEVA icon
10
CALL
Teva Pharmaceuticals
TEVA
$37.3B
$18.7M 2.15%
1,150,000
-505,000
-31% -$7.78M
CLDX icon
11
Celldex Therapeutics
CLDX
$2.77B
$17.6M 2.03%
475,400
-34,600
-7% -$1.31M
ONC
12
BeOne Medicines Ltd
ONC
$32.4B
$15.7M 1.81%
110,000
+27,857
+34% +$4.29M
ALKS icon
13
Alkermes
ALKS
$8.79B
$15.7M 1.81%
650,000
+575,000
+767% +$14.1M
NUVL
14
DELISTED
Nuvalent
NUVL
$15.2M 1.75%
200,000
+50,000
+33% +$3.56M
AUTL
15
Autolus Therapeutics
AUTL
$383M
$15M 1.72%
4,300,000
+925,000
+27% +$3.99M
VERA icon
16
Vera Therapeutics
VERA
$2.76B
$13.6M 1.56%
375,000
-95,000
-20% -$3.77M
KURA icon
17
Kura Oncology
KURA
$964M
$13.4M 1.54%
650,000
-80,492
-11% -$1.65M
INZY
18
DELISTED
Inozyme Pharma
INZY
$12.7M 1.47%
2,856,252
+213,733
+8% +$1.04M
SYRE icon
19
Spyre Therapeutics
SYRE
$8.7B
$12.1M 1.39%
513,420
+103,420
+25% +$3.49M
CLYM
20
Climb Bio
CLYM
$727M
$11.9M 1.37%
+1,670,661
New +$11.1M
CNTA
21
DELISTED
Centessa Pharmaceuticals
CNTA
$10.3M 1.18%
1,135,702
+305,156
+37% +$2.89M
CERE
22
CALL
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$10.2M 1.18%
+250,000
New +$10.4M
ESTA icon
23
Establishment Labs
ESTA
$2.72B
$10.2M 1.17%
223,407
+58,818
+36% +$2.98M
VRNA
24
DELISTED
Verona Pharma
VRNA
$10.1M 1.17%
700,000
-117,833
-14% -$1.72M
NARI
25
DELISTED
Inari Medical, Inc. Common Stock
NARI
$9.63M 1.11%
200,000
+25,000
+14% +$1.11M
1
2 3 4 5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, Affinity Asset Advisors held 127 positions worth $868M, up 7.4% from $808M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Affinity Asset Advisors deployed $69.5M of net new capital in Q2 2024, opening 31 new positions and adding to 30 existing holdings. Its largest new stake was Climb Bio: 1,670,661 shares worth $11.9M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, down from 71% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Axsome Therapeutics, an estimated $4.42M trimmed.

  • Affinity Asset Advisors's largest Q2 2024 buy was Climb Bio: 1,670,661 shares worth $11.9M.
  • Affinity Asset Advisors added most to Alkermes in Q2 2024, an estimated $14.1M increase.
  • Affinity Asset Advisors's biggest Q2 2024 reduction was Axsome Therapeutics, cutting an estimated $4.42M.
  • Affinity Asset Advisors fully exited Apellis Pharmaceuticals in Q2 2024, selling an estimated $9.7M.
  • Affinity Asset Advisors's ten largest holdings make up 49% of its $868M portfolio in Q2 2024.
  • Affinity Asset Advisors opened 31 new positions and closed 29 in Q2 2024.
  • Affinity Asset Advisors's portfolio value rose 7.4% quarter-over-quarter to $868M.

Based on Affinity Asset Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.